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In this issue of the Journal of Thoracic Oncology, Yang et al.1 contribute knowledge ofimportance to all of us treating lung cancer, and their findings may have larger
implications for monitoring and analysis in many areas of cancer therapy. By incorpo-
rating quality of life (QOL) and patient-reported outcome (PRO) assessment into an
analysis of lung cancer patients with long-term survival, we obtain an enhanced knowl-
edge of issues affecting these individuals and can plan for interventions which may benefit
specific patients.
Most patients in this report had lung cancer surgery, with or without adjuvant
therapies, and were monitored at 3 and 5 years for effects on QOL and PROs. Key findings
of this analysis include meaningful decreases in QOL associated with worsened symptoms
in 35% of patients over the time of follow-up. Although this worsening is worrisome, the
optimist may point out that 65% of patients experienced either improvement in QOL and
symptoms or no decrease in the long-term setting after having had definitive treatment for
the leading cause of cancer-related death in many countries. The findings in this analysis
of more than 400 patients are supported by a prior smaller trial with shorter follow-up in
patients undergoing neoadjuvant therapy, using the same QOL instrument.2 Yang et al.
proposed that by monitoring QOL and PROs with the use of a simple and well-validated
QOL instrument (the Lung Cancer Symptom Scale [LCSS]) with demonstrated high
patient acceptance,3 one can identify patients experiencing problems. Personalized inter-
ventions can then be targeted to address these issues. I would add that this study provides
high-quality information which should be discussed with patients before treatment so that
they can be better informed about long-term risks and benefits of these complicated
treatments. For the future, it is easy to see that similar analyses could be conducted to
compare open thoracotomy with video-assisted thoracoscopic surgery or with stereotactic
radiotherapy to understand more fully the value of these different procedures.
This trial raises several methodologic issues. The design is a longitudinal analysis
using patients as their own controls. In such an analysis, it is important to keep a high
percentage of patients in the analysis. The 77% of patients retained seem to be acceptable.
The study would have greater context if there had been a concurrent age-matched control
group without lung cancer, with a similar percentage of smokers monitored for QOL and
PROs over the 3 to 5 years. It is sobering to realize that we are not aware of the magnitude
of the decline in QOL and pulmonary symptoms in a largely smoking population over this
time. It is possible that many of the issues experienced by these survivors are only partially
due to therapy.
The authors allude to an important trade-off in QOL evaluation. To retain a high
percentage of patients in a study, the QOL instrument must be feasible. Instruments that
are perceived to be too burdensome run the risk of discouraging patients from continuing
in the trial, threatening the credibility of the study if excessive numbers drop out. On the
other hand, the authors voice that there may have been even more value if they had added
other instruments assessing emotional and other issues in greater depth. More information
can be interesting and desirable; however, the added burden of more questions might have
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affected the number of patients remaining in the study. In
addition, analysis issues may arise when a study assesses
dozens of end points and uses instruments not validated in
lung cancer. Choosing a validated instrument that addresses
well the specified key QOL and PRO areas is crucial in study
design, as is a thoughtful prospective analysis plan. All
investigators need to appreciate the great deal of work and
expense that has gone into the development of such validated
lung cancer instruments as the LCSS, the EORTC-QLQ
LC-13, and the Functional Assessment of Cancer Therapy-
Lung (FACT-L) which are available in more than 50 lan-
guages. The latest versions of the instruments should be used,
their copyrights must be respected, and the designated pro-
cedures need to be followed.
In a larger scope, this study illustrates major consider-
ations for oncology trials and clinical evaluation. The study
demonstrates that large numbers of patients can be evaluated
when using practical QOL methods. It clearly shows that
such evaluations yield valuable information that is not oth-
erwise obtainable. Finally, the study is an example of the
sensitivity and accuracy of validated instruments. As exam-
ples, patients with decreases in QOL had more symptom
worsening; and compared with those having just lobectomy,
patients undergoing larger resections had greater impacts
on QOL and symptoms. These were consistent findings
across time points and across symptoms. Such findings
should give greater confidence in the accuracy of validated
QOL instruments.
If QOL assessment is to take its full position in treat-
ment evaluation and patient care, existing barriers must be
overcome. With the LCSS, a hand-held computer-assisted
version (“eLCSS-QL”) is now widely tested with high patient
acceptance and low staff burden. Nonetheless, there is some
modest cost to QOL and PRO assessment. Payers will need to
reimburse for these assessments if QOL assessments are to
become part of daily practice. Prospective studies are needed
to demonstrate the likelihood that these assessments are cost
saving, in addition to their great clinical value as illustrated
by Yang et al. It is time for QOL and PRO assessment to
come of age in lung cancer and in all cancer care.
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